VRDN

+ Watchlist + Portfolio

Viridian Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $24.80
52-Week Range: $13.18 – $34.29
Market Cap: $2.78B
P/E (TTM): —
EPS (TTM): -3.40
Dividend Yield: —

Advanced Metrics

Price/Book: 4.98
PEG Ratio: —
Return on Equity: -65.74%
Return on Assets: -30.16%
Gross Margin: 0.00%
Operating Margin: -44460.56%
Profit Margin: 0.00%
Current Ratio: 16.95
Debt/Equity: 0.37
Total Debt: $244.73M
Free Cash Flow: $-275.50M
Revenue Growth: 278.70%
Earnings Growth: —
Enterprise Value: $2.17B

VRDN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.77M	$314.00K	$302.00K	$70.85M
Research & Development	$100.89M	$159.76M	$238.25M	$338.93M
Selling, General & Admin	$35.18M	$95.00M	$61.08M	$95.31M
Operating Expenses	$136.08M	$254.76M	$299.34M	$434.24M
Operating Income	-$134.30M	-$254.45M	-$299.04M	-$363.39M
EBITDA	-$129.13M	-$235.88M	-$267.21M	-$337.19M
Pretax Income	-$129.87M	-$237.73M	-$269.95M	-$342.60M
Net Income	-$129.87M	-$237.73M	-$269.95M	-$342.60M
Diluted EPS	-4.05	-5.31	-3.07	-3.32
Diluted Shares	32.09M	44.76M	67.89M	84.80M

VRDN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$155.58M	$102.83M	$99.59M	$212.38M
Receivables	$102.00K	$102.00K	$0.00	—
Current Assets	$431.17M	$486.48M	$738.46M	$894.23M
Total Assets	$435.09M	$490.42M	$742.40M	$899.42M
Current Liabilities	$33.35M	$26.64M	$47.87M	$70.70M
Long-Term Debt	$4.64M	$20.20M	$20.58M	$49.94M
Total Debt	$5.26M	$21.05M	$21.09M	$50.69M
Total Liabilities	$40.03M	$48.40M	$70.76M	$177.25M
Retained Earnings	-$488.17M	-$725.91M	-$995.86M	-$1.34B
Shareholders' Equity	$395.06M	$442.02M	$671.64M	$722.17M
Working Capital	$397.82M	$459.84M	$690.59M	$823.54M

VRDN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$93.84M	-$184.17M	-$232.32M	-$276.39M
Capital Expenditure	-$797.00K	-$898.00K	-$511.00K	-$495.00K
Free Cash Flow	-$94.64M	-$185.07M	-$232.83M	-$276.89M
Depreciation & Amortisation	$255.00K	$522.00K	$540.00K	$460.00K
Stock-Based Compensation	$19.77M	$67.17M	$42.15M	$44.30M
Investing Cash Flow	-$115.13M	-$94.25M	-$228.65M	-$37.56M
Financing Cash Flow	$322.24M	$225.67M	$457.74M	$426.74M
Net Change in Cash	$113.28M	-$52.75M	-$3.23M	$112.79M

VRDN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$72.00K	$75.00K	$70.57M	$132.00K	$141.00K
Research & Development	$76.83M	$86.63M	$86.26M	$89.21M	$77.63M
Selling, General & Admin	$17.10M	$20.22M	$24.32M	$33.67M	$38.68M
Operating Expenses	$93.94M	$106.84M	$110.58M	$122.88M	$116.31M
Operating Income	-$93.87M	-$106.77M	-$40.01M	-$122.75M	-$116.17M
EBITDA	-$86.25M	-$100.11M	-$33.93M	-$116.95M	-$101.32M
Pretax Income	-$86.91M	-$100.73M	-$34.60M	-$120.36M	-$104.90M
Net Income	-$86.91M	-$100.73M	-$34.60M	-$120.36M	-$104.90M
Diluted EPS	-0.87	-1.00	-0.34	-1.08	-0.90
Diluted Shares	81.34M	81.59M	81.78M	94.38M	102.21M

VRDN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$116.22M	$117.32M	$169.65M	$212.38M	$176.35M
Receivables	$0.00	$0.00	$70.00M	—	—
Current Assets	$657.24M	$578.75M	$571.91M	$894.23M	$784.74M
Total Assets	$660.98M	$582.32M	$577.14M	$899.42M	$789.02M
Current Liabilities	$33.73M	$52.59M	$50.70M	$70.70M	$51.80M
Long-Term Debt	$20.68M	$12.35M	$20.89M	$49.94M	$50.44M
Total Debt	$21.22M	$21.34M	$21.62M	$50.69M	$51.17M
Total Liabilities	$56.51M	$67.16M	$74.17M	$177.25M	$153.01M
Retained Earnings	-$1.08B	-$1.18B	-$1.22B	-$1.34B	-$1.44B
Shareholders' Equity	$604.47M	$515.17M	$502.97M	$722.17M	$636.01M
Working Capital	$623.51M	$526.16M	$521.22M	$823.54M	$732.94M

VRDN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$92.65M	-$75.37M	-$84.61M	-$23.75M	-$119.65M
Capital Expenditure	-$86.00K	-$42.00K	-$127.00K	-$240.00K	-$23.00K
Free Cash Flow	-$92.74M	-$75.42M	-$84.74M	-$23.99M	-$119.68M
Depreciation & Amortisation	$117.00K	$113.00K	$110.00K	$120.00K	$121.00K
Stock-Based Compensation	$10.22M	$10.84M	$11.25M	$11.99M	$13.39M
Investing Cash Flow	$100.06M	$75.72M	$126.08M	-$339.42M	$77.26M
Financing Cash Flow	$9.21M	$764.00K	$10.86M	$405.91M	$6.36M
Net Change in Cash	$16.62M	$1.11M	$52.32M	$42.73M	-$36.04M

Market Snapshot

About

Viridian Therapeutics, Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases with significant unmet medical needs. The company is focused on developing novel therapies for thyroid eye disease and other autoimmune conditions. Viridian leverages innovative antibody technology to create potentially transformative medicines.